目的 探究银黄清肺胶囊联合莫西沙星治疗慢性阻塞性肺疾病急性加重的临床疗效。方法 纳入2024年5月—2025年10月于沈阳医学院附属中心医院住院治疗的慢性阻塞性肺疾病急性加重患者112例，采用简单随机抽样的方式将受试者分为对照组和治疗组，每组各56例。对照组患者静脉滴注盐酸莫西沙星注射液，临用前用5%葡萄糖注射液250 mL稀释，1支/次，1次/d，持续滴注5 d。治疗组在对照组基础上口服银黄清肺胶囊，3粒/次，3次/d，连续给药5 d。比较两组患者临床总有效率，临床症状好转时间、治疗前后肺功能指标第1秒用力呼气量（FEV1）、用力肺活量（FVC）、FEV1/FVC、最大通气量（MVV）、血清炎性因子C反应蛋白（CRP）、白细胞介素-4（IL-4）、IL-8、IL-18和肿瘤坏死因子-α（TNF-α）水平。结果 与对照组（82.14%）相比，治疗组总有效率显著提升至94.64%（P＜0.05），且咳嗽、咳痰、胸闷、乏力好转时间更短（P＜0.05）。肺功能及血清炎性因子检测结果显示，治疗后两组FEV1、FVC、FEV1/FVC、MVV和IL-4水平均较基线期升高，血清CRP、IL-8、IL-18、TNF-α水平均较基线期降低（P＜0.05），且治疗组的肺功能改善效果及炎性因子抑制效果均显著优于对照组（P＜0.05）。结论 银黄清肺胶囊联合莫西沙星对慢性阻塞性肺疾病急性加重患者的疗效显著，能够加速临床症状好转，改善肺功能，抑制炎症反应，安全性高。

Objective To explore the clinical efficacy of Yinhuang Qingfei Capsules combined with moxifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 112 hospitalized patients with AECOPD admitted to the Central Hospital Affiliated to Shenyang Medical College between May 2024 and October 2025 were enrolled in this study. Subjects were randomly assigned to a control group and a treatment group using simple random sampling, with 56 patients in each group. Patients in the control group received intravenous infusion of moxifloxacin hydrochloride injection diluted with 250 mL of 5% glucose solution before use, one vial once daily for 5 consecutive days. On the basis of the control regimen, patients in the treatment group additionally received oral Yinhuang Qingfei Capsules at a dose of 3 capsules three times daily for 5 consecutive days. The overall clinical response rate, time to improvement of clinical symptoms, and changes in pulmonary function indicators including forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and maximal voluntary ventilation (MVV), as well as serum inflammatory factors C-reactive protein (CRP), interleukin-4 (IL-4), IL-8, IL-18 and tumor necrosis factor-α (TNF-α) before and after treatment were compared between the two groups. Results The overall clinical response rate in the treatment group reached 94.64%, which was significantly higher than 82.14% in the control group (P < 0.05). Meanwhile, the treatment group exhibited shorter remission time for cough, expectoration, chest tightness and fatigue (P < 0.05). Pulmonary function and serum inflammatory factor analyses demonstrated that FEV1, FVC, FEV1/FVC, MVV and IL-4 levels increased, whereas serum CRP, IL-8, IL-18 and TNF-α levels decreased after treatment in both groups relative to baseline (P < 0.05). Moreover, the treatment group achieved superior improvements in pulmonary function and stronger suppression of inflammatory responses compared with the control group (P < 0.05). Conclusion Yinhuang Qingfei Capsules combined with moxifloxacin exerts promising therapeutic effects in patients with AECOPD. This combination regimen accelerates the relief of clinical symptoms, improves pulmonary function, inhibits inflammatory reactions, and maintains favorable safety profiles.

R974

辽宁省重点研发计划指导计划项目（2024045030）